参考文献/References:
[1] Han Q,Zhu H,Chen X,et al.Non-genetic mechanisms of diabetic nephropathy[J].Front Med,2017,11(3):319-332.DOI:10.1007/s11684-017-0569-9.
[2] Zhang L,Long J,Jiang W,et al.Trends in chronic kidney disease in China[J].N Engl J Med,2016,375(9):905-906. DOI:10.1056/NEJMc1602469.
[3] Kanwar YS,Sun L,Xie P,et al.A glimpse of various pathogenetic mechanisms of diabetic nephropathy[J].Annu Rev Pathol,2011,6:395-423.DOI:10.1146/annurev.pathol.4.110807.092150.
[4] Galsgaard J,Persson F,Hansen TW,et al.Plasma high-sensitivity troponin T predicts end-stage renal disease and cardiovascular and all-cause mortality in patients with type 1 diabetes and diabetic nephropathy[J].Kidney Int,2017,92(5):1242-1248.DOI:10.1016/j.kint.2017.04.018.
[5] Kimenai DM,Henry RM,van der Kallen CJ,et al.Direct comparison of clinical decision limits for cardiac troponin T and I[J].Heart,2016,102(8):610-616.DOI:10.1136/heartjnl-2015-308917.
[6] Than MP,Aldous SJ,Troughton RW,et al.Detectable high-sensitivity cardiac troponin within the population reference interval conveys high 5-year cardiovascular risk: an Observational Study[J].Clin Chem,2018,64(7):1044-1053.DOI:10.1373/clinchem.2017.285700.
[7] Biener M,Giannitsis E,Kuhner M,et al.Risk prediction in stable cardiovascular disease using a high-sensitivity cardiac troponin T singlebiomarker strategy compared to the ESC-SCORE[J].Open Heart,2018,5(1):e000710.DOI:10.1136/openhrt-2017-000710.
[8] Ballew SH,Matsushita K.Cardiovascular risk prediction in CKD[J].Semin Nephrol,2018,38(3):208-216.DOI:10.1016/j.semnephrol.2018.02.002.
[9] Swoboda PP,McDiarmid AK,Erhayiem B,et al.Diabetes mellitus, microalbuminuria, and subclinical cardiac disease: identification and monitoring of individuals at risk of heart failure[J].J Am Heart Assoc,2017,6(7):pii: e005539.DOI:10.1161/JAHA.117.005539.
[10] Giannitsis E,Katus HA.Cardiac troponin level elevations not related to acute coronary syndromes[J].Nat Rev Cardiol,2013,10(11):623-634.DOI:10.1038/nrcardio.2013.129.
[11] Fioretto P,Avogaro A.Dapagliflozin:potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes[J].Expert Opin Pharmacother,2017,18(5):517-527.DOI:10.1080/14656566.2017.1300253.
[12] Gidding SS,Bacha F,Bjornstad P,et al.Cardiac biomarkers in youth with type 2 diabetes mellitus: results from the TODAY study[J].J Pediatr,2018,192:86-92.e5.DOI:10.1016/j.jpeds.2017.09.012.
[13] Langsford D,Tang M,Cheikh Hassan HI,et al.The association between biomarker profiles, etiology of chronic kidney disease, and mortality[J].Am J Nephrol,2017,45(3):226-234.DOI:10.1159/000454991.
[14] Kim H,Yoo TH,Choi KH,et al.Baseline cardiovascular characteristics of adult patients with chronic kidney disease from the KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease(KNOW-CKD)[J].J Korean Med Sci,2017,32(2):231-239.DOI:10.3346/jkms.2017.32.2.231.
[15] Feldman EL,Nave KA,Jensen TS,et al.New horizons in diabetic neuropathy: mechanisms, bioenergetics, and pain[J].Neuron,2017,93(6):1296-1313.DOI:10.1016/j.neuron.2017. 02.005.
[16] Ghosh N,Katare R.Molecular mechanism of diabetic cardiomyopathy and modulation of microRNA function by synthetic oligonucleotides[J].Cardiovasc Diabetol,2018,17(1):43.DOI:10.1186/s12933-018-0684-1.
[17] Schilling JD.The mitochondria in diabetic heart failure:from pathogenesis to therapeutic promise[J].Antioxid Redox Signal,2015,22(17):1515-1526.DOI:10.1089/ars.2015.6294.
[18] Galloway CA,Yoon Y.Mitochondrial dynamics in diabetic cardiomyopathy[J].Antioxid Redox Signal,2015,22(17):1545-1562.DOI:10.1089/ars.2015.6293.
[19] Patney V,Chaudhary K,Whaley-Connell A.Treatment of diabetic kidney disease with hypertension control and renin angiotensin system inhibition[J].Adv Chronic Kidney Dis,2018,25(2):158-165.DOI:10.1053/j.ackd.2017.11.002.
[20] King RJ,Grant PJ.Diabetes and cardiovascular disease:pathophysiology of a life-threatening epidemic[J].Herz,2016,41(3):184-192.DOI:10.1007/s00059-016-4414-8.
[21] Di Lullo L,Bellasi A,Barbera V,et al.Pathophysiology of the cardio-renal syndromes types 1-5:an uptodate[J].Indian Heart J,2017,69(2):255-265.DOI:10.1016/j.ihj.2017.01.005.
[22] Lee WS,Kim J.Diabetic cardiomyopathy: where we are and where we are going[J].Korean J Intern Med,2017,32(3):404-421.DOI:10.3904/kjim.2016.208.
[23] Hellemons ME,Lambers Heerspink HJ,Gansevoort RT,et al.High-sensitivity troponin T predicts worsening of albuminuria in hypertension; results of a nestedcase-control study with confirmation in diabetes[J].J Hypertens,2013,31(4):805-812.DOI:10.1097/HJH.0b013e32835eb5e8.
[24] Felício JS,Koury CC,Carvalho CT,et al.Present insights on cardiomyopathy in diabetic patients[J].Curr Diabetes Rev,2016,12(4):384-395.
[25] Selvin E,Lazo M,Chen Y,et al.Diabetes mellitus, prediabetes, and incidence of subclinical myocardial damage[J].Circulation,2014,130(16):1374-1382.DOI:10.1161/CIRCULATIONAHA.114.010815.
[26] Desai AS,Toto R,Jarolim P,et al.Association between cardiac biomarkers and the development of ESRD in patients with type 2diabetes mellitus, anemia, and CKD[J].Am J Kidney Dis,2011,58(5):717-728.DOI:10.1053/j.ajkd.2011.05.020.
[27] de Lemos JA,Drazner MH,Omland T,et al.Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population[J].JAMA,2010,304(22):2503-2512.DOI:10.1001/jama.2010.1768.
[28] Umanath K,Lewis JB.Update on diabetic nephropathy: core curriculum 2018[J].Am J Kidney Dis,2018,71(6):884-895.DOI:10.1053/j.ajkd.2017.10.026.
[29] Welsh P,Woodward M,Hillis GS,et al.Do cardiac biomarkers NT-proBNP and hsTnT predict microvascular events in patients with type 2 diabetes results from the ADVANCE trial[J].Diabetes Care,2014,37(8):2202-2210.DOI:10.2337/dc13-2625.
[30] Bidadkosh A,Lambooy SPH,Heerspink HJ,et al.Predictive properties of biomarkers GDF-15, NTproBNP, and hs-TnT for morbidity and mortality in patients with type 2 diabetes with nephropathy[J].Diabetes Care,2017,40(6):784-792.DOI:10.2337/dc16-2175.
[31] Jenks SJ,Conway BR,McLachlan S,et al.Cardiovascular disease biomarkers are associated with declining renal function in type 2 diabetes[J].Diabetologia,2017,60(8):1400-1408.DOI:10.1007/s00125-017-4297-0.
相似文献/References:
[1].2007年糖尿病新进展学习班将举办[J].国际内分泌代谢杂志,2007,(04):226.
[2]李英,段惠军.Raf/MEK/ERK信号转导通路在糖尿病肾病发生发展中的作用[J].国际内分泌代谢杂志,2007,(04):264.
[3]张红 章向成 朱大龙.炎性反应与糖尿病肾病[J].国际内分泌代谢杂志,2015,(01):49.[doi:10.3760/cma.j.issn.1673-4157.2015.01.012]
Zhang Hong*,Zhang Xiangcheng,Zhu Dalong..Role of inflammation in diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(03):49.[doi:10.3760/cma.j.issn.1673-4157.2015.01.012]
[4]邵滢,王秋月.Mir-217/Sirt1通路与糖尿病肾病[J].国际内分泌代谢杂志,2015,(02):124.[doi:10.3760/cma.j.issn.1673-4157.2015.02.014]
Shao Ying,Wang Qiuyue..Mir-217 / Sirt1 pathway and diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(03):124.[doi:10.3760/cma.j.issn.1673-4157.2015.02.014]
[5]王洁,何媛,于珮.糖尿病肾病的相关危险因素分析[J].国际内分泌代谢杂志,2015,(03):153.[doi:10.3760/cma.j.issn.1673-4157.2015.03.003]
Wang Jie*,He Yuan,Yu Pei..Risk factors of diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(03):153.[doi:10.3760/cma.j.issn.1673-4157.2015.03.003]
[6]任慧雯,王秋月.Epac-Rap1与糖尿病肾病[J].国际内分泌代谢杂志,2015,(03):170.[doi:10.3760/cma.j.issn.1673-4157.2015.03.007]
Ren Huiwen,Wang Qiuyue..Epac-Rap1 and diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(03):170.[doi:10.3760/cma.j.issn.1673-4157.2015.03.007]
[7]邵滢,王秋月.MiRNA-150与糖尿病肾病[J].国际内分泌代谢杂志,2015,(03):173.[doi:10.3760/cma.j.issn.1673-4157.2015.03.008]
Shao Ying,Wang Qiuyue..MiRNA-150 and diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(03):173.[doi:10.3760/cma.j.issn.1673-4157.2015.03.008]
[8]陈堃,刘超,陈国芳,等.糖尿病肾病诊断标志物研究进展[J].国际内分泌代谢杂志,2015,(03):176.[doi:10.3760/cma.j.issn.1673-4157.2015.03.009]
Chen Kun,Liu Chao,Chen Guofang,et al.Urinary biomarkers for diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(03):176.[doi:10.3760/cma.j.issn.1673-4157.2015.03.009]
[9]任慧雯,王秋月.Vasohibin-1与糖尿病肾病[J].国际内分泌代谢杂志,2015,(04):246.[doi:10.3760/cma.j.issn.1673-4157.2015.04.008]
Ren Huiwen,Wang Qiuyue..Vasohibin-1 and diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(03):246.[doi:10.3760/cma.j.issn.1673-4157.2015.04.008]
[10]安丽,王秋月.Visfatin与胰岛素抵抗及糖尿病肾病的发病机制[J].国际内分泌代谢杂志,2015,(04):248.[doi:10.3760/cma.j.issn.1673-4157.2015.04.009]
An Li,Wang Qiuyue..Visfatin in the pathogenesis of insulin resistance and diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(03):248.[doi:10.3760/cma.j.issn.1673-4157.2015.04.009]